GlaxoSmithKline PLC
07 April 2003
Director's Interests
I give below details of changes in director's interests in the Ordinary Shares
of GlaxoSmithKline plc.
The Administrators of the GlaxoSmithKline US Retirement
Savings Plan ("the Plan") notified GlaxoSmithKline plc on 4
April 2003, that as a result of movement in the fund on the
4 April 2003, the number of Ordinary Share ADRs held by the
fund had decreased from 18,642,142 to 18,586,757 at an
average price of $36.89.
The Plan is a discretionary fund of which all employees or former employees of
GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. One of the
Company's directors, Dr J P Garnier is therefore potentially interested in the
shares held in the fund from time to time in the same way as other employees or
former employees of GlaxoSmithKline plc and its subsidiaries.
S M Bicknell
Company Secretary
7 April 2003
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.